Skip to main content
BCAX
NASDAQ Life Sciences

Bicara Q3 Loss Widens to $71.2M; $442.3M Cash Funds Operations Into 1H 2029

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$8.65
Mkt Cap
$572.396M
52W Low
$7.87
52W High
$30.99
52W Position info
9.9% above low
Off High info
72% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

BCAX is trading near its 52-week low of $7.87 (9.9% above the low).

Summary

Bicara reported a wider Q3 2026 loss of $71.2M as trial and commercialization spending ramped, while $442.3M in cash extends its runway into the first half of 2029 — past the mid-2027 interim data from its pivotal head and neck cancer trial.

Updates

  1. · Reuters — Bicara Therapeutics reported a quarterly adjusted loss of $1.04 per share for the quarter ended September 30, versus the mean expectation of fourteen analysts for a loss of 83 cents per share.

    • Reported revenue was zero; analysts expected zero.
    • Quarterly net loss: $71.25 million.

Key Events · Earnings and Guidance · BCAX

  • Q3 Loss Widens on Trial Spend

    Net loss was $71.2M ($1.04 per share) versus $36.3M ($0.67) in Q3 2025, driven by R&D of $56.5M (up from $33.0M) and G&A of $19.2M (up from $7.7M).

  • Cash Runway Extended to 1H 2029

    Cash, equivalents and marketable securities totaled $442.3M at September 30, 2026, up from $414.8M at December 31, 2025, funding operations into the first half of 2029.

  • Pivotal Trial Fully Enrolled

    Bicara achieved substantial enrollment in the FORTIFI-HN01 pivotal trial in 1L R/M HPV-negative HNSCC, with topline interim results expected mid-2027.

  • Alternate Dosing Study Enrolling

    FORTIFI-FLEX is testing a 12-week 1500mg weekly loading dose followed by 2250mg every three weeks versus 1500mg weekly, each with pembrolizumab; data expected by potential U.S. approval.


Analysis · BCAX · Life Sciences

The balance sheet is the story here: $442.3M in cash and securities carries Bicara into the first half of 2029, past the mid-2027 interim readout that will decide the program's value. The loss widened sharply as the company spends to run its pivotal head and neck cancer trial and build a commercial team. Investors are paying for that readout, so the key question is whether spending at this pace holds through the data. No financing is needed near term, which removes the dilution overhang that usually hangs over clinical-stage names.

How filings like this one have moved

In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BCAX was trading at $8.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $572.4M. The 52-week trading range was $7.87 to $30.99. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BCAX - Latest Insights

BCAX
Aug 11, 2026, 4:46 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $23.77
Real-time Price: $8.91 info
Change: -$14.86 (-63%) info
Market Cap: $594.233M info
BCAX
Aug 11, 2026, 7:36 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $28.09
Real-time Price: $8.91 info
Change: -$19.18 (-68%) info
Market Cap: $594.233M info
BCAX
Aug 11, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $28.09
Real-time Price: $8.91 info
Change: -$19.18 (-68%) info
Market Cap: $594.233M info
BCAX
Jun 01, 2026, 4:02 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $20.62
Real-time Price: $8.91 info
Change: -$11.71 (-57%) info
Market Cap: $594.233M info
BCAX
May 21, 2026, 5:04 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $20.84
Real-time Price: $8.91 info
Change: -$11.93 (-57%) info
Market Cap: $594.233M info